092730 — NeoPharm Co Balance Sheet

0.000.00%

Last trade - 00:00

Consumer DefensivesAdventurousSmall CapSuper Stock

Market Cap
KR₩256bn
Enterprise Value
KR₩127bn
Revenue
KR₩119bn

Annual balance sheet for NeoPharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	96,181	105,049	113,485	111,990	126,524
Net Total Accounts Receivable
Net Total Receivables	8,863	8,045	7,665	10,383	12,762
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	113,551	121,484	131,270	134,502	153,050
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	10,121	9,743	9,341	29,244	29,764
Net Intangible Assets
Long Term Investments
Long Term Notes Receivable
Other Long Term Assets
Total Assets	132,978	143,408	155,347	177,459	192,440
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	14,877	12,941	13,137	16,945	15,128
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Minority Interest
Total Other Liabilities
Total Funded Status
Total Liabilities	15,260	13,103	13,137	17,433	15,555
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Treasury Stock
ESOP Debt Guarantee
Unrealized Gain / Loss
Other Equity
Total Equity	117,718	130,305	142,211	160,026	176,885
Total Liabilities & Shareholders' Equity	132,978	143,408	155,347	177,459	192,440
Total Common Shares Outstanding